ATE204579T1 - Proteinkinase c-inhibitoren - Google Patents

Proteinkinase c-inhibitoren

Info

Publication number
ATE204579T1
ATE204579T1 AT94308947T AT94308947T ATE204579T1 AT E204579 T1 ATE204579 T1 AT E204579T1 AT 94308947 T AT94308947 T AT 94308947T AT 94308947 T AT94308947 T AT 94308947T AT E204579 T1 ATE204579 T1 AT E204579T1
Authority
AT
Austria
Prior art keywords
protein kinase
inhibitors
indolemaleimide
mammals
chem
Prior art date
Application number
AT94308947T
Other languages
English (en)
Inventor
William Francis Heath Jr
Michael Robert Jirousek
John Hampton Mcdonald Iii
Christopher John Rito
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE204579T1 publication Critical patent/ATE204579T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/17—Unsaturated ethers containing halogen
    • C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
    • C07C43/1745—Unsaturated ethers containing halogen containing six-membered aromatic rings having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT94308947T 1993-12-07 1994-12-02 Proteinkinase c-inhibitoren ATE204579T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16306093A 1993-12-07 1993-12-07
US31697394A 1994-10-03 1994-10-03

Publications (1)

Publication Number Publication Date
ATE204579T1 true ATE204579T1 (de) 2001-09-15

Family

ID=26859318

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94308947T ATE204579T1 (de) 1993-12-07 1994-12-02 Proteinkinase c-inhibitoren

Country Status (30)

Country Link
US (1) US5698578A (de)
EP (1) EP0657458B1 (de)
JP (2) JP3581731B2 (de)
KR (1) KR100340159B1 (de)
CN (2) CN1050844C (de)
AT (1) ATE204579T1 (de)
AU (1) AU687909B2 (de)
BR (1) BR9404831A (de)
CA (1) CA2137203C (de)
CO (1) CO4340622A1 (de)
CY (1) CY2413B1 (de)
CZ (1) CZ291950B6 (de)
DE (1) DE69428025T2 (de)
DK (1) DK0657458T3 (de)
ES (1) ES2162843T3 (de)
FI (3) FI108138B (de)
GR (1) GR3037087T3 (de)
HU (1) HU219709B (de)
IL (1) IL111850A (de)
MY (1) MY125587A (de)
NO (1) NO308798B1 (de)
NZ (1) NZ270048A (de)
PE (1) PE49195A1 (de)
PL (1) PL182124B1 (de)
PT (1) PT657458E (de)
RU (1) RU2147304C1 (de)
SG (1) SG63570A1 (de)
TW (1) TW425397B (de)
UA (1) UA44690C2 (de)
YU (1) YU49200B (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
DK0776899T3 (da) 1995-11-20 2000-07-10 Lilly Co Eli Mellemprodukter og deres anvendelse til fremstilling af N,N'-forbundne bisindolylmaleimider
UA61897C2 (en) * 1995-11-20 2003-12-15 Lilly Co Eli Protein kinase c inhibitors, methods for synthesis, pharmaceutical formulations and methods for treating microvascular diabetic complications
US5919946A (en) * 1996-03-20 1999-07-06 Eli Lilly And Company Synthesis of indolylmaleimides
EA001450B1 (ru) * 1996-05-01 2001-04-23 Эли Лилли Энд Компани Галогензамещенные ингибиторы протеинкиназы с
AU736333B2 (en) * 1996-05-01 2001-07-26 Eli Lilly And Company Therapeutic treatment for VEGF related diseases
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
US6093709A (en) * 1996-08-22 2000-07-25 Eli Lilly And Company Therapeutic treatment for sexual dysfunctions
US6107327A (en) * 1996-08-30 2000-08-22 Eli Lilly And Company Therapeutic treatment for HIV infection
PL331761A1 (en) * 1996-08-30 1999-08-02 Lilly Co Eli Application of pkc inhibitors in production of a drug for treating central nervous system diseases associated with hiv infections
WO1998008510A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
US5962446A (en) * 1996-08-30 1999-10-05 Eli Lilly And Company Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
US5721272A (en) * 1996-11-18 1998-02-24 Eli Lilly And Company Intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
JPH1135454A (ja) * 1997-07-22 1999-02-09 Meiji Milk Prod Co Ltd 抗腫瘍剤
DE69940423D1 (de) 1998-01-30 2009-04-02 Daiso Co Ltd Verfahren zur herstellung von butantriol-derivaten
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
US6291446B1 (en) 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
US6225301B1 (en) * 1998-03-05 2001-05-01 Eli Lilly And Company Therapeutic treatment for renal dysfunction
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
AU758241B2 (en) * 1998-03-13 2003-03-20 University Of British Columbia, The Granulatimide derivatives for use in cancer treatment
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6492406B1 (en) * 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
CA2431187A1 (en) * 2000-12-08 2002-06-13 Ortho-Mcneil Pharmaceutical, Inc. Macroheterocylic compounds useful as kinase inhibitors
DE10109280A1 (de) * 2001-02-26 2002-09-05 Peter Mayser Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
ES2280596T3 (es) * 2001-12-29 2007-09-16 Novo Nordisk A/S Uso combinado de un compuesto de glp-1 y un inhibidor de una aldosa reductasa.
US6887864B2 (en) 2002-03-12 2005-05-03 Hoffmann-La Roche Inc. Azepane derivatives
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
DE10233737A1 (de) * 2002-07-24 2004-02-05 Morphochem Aktiengesellschaft für kombinatorische Chemie Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen
WO2004111077A1 (en) 2003-06-18 2004-12-23 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor
BRPI0413439A (pt) 2003-08-08 2006-10-17 Novartis Ag combinações compreendendo estaurosporinas
EP1745037B1 (de) * 2004-01-19 2013-01-02 Novartis AG Zur Behandlung von Transplantatabstossung oder Autoimmunerkrankungen geeignete Indolylmaleimidderivate
NZ550340A (en) * 2004-03-17 2010-08-27 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle using a retinoid
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
WO2006108270A1 (en) * 2005-04-11 2006-10-19 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
US7759331B2 (en) 2006-03-10 2010-07-20 Janssen Pharmaceutica Nv Pyridine-containing macroheterococylic compounds as kinase inhibitors
EP2181999A1 (de) 2008-11-03 2010-05-05 Zentiva, A.S. Verfahren zur Herstellung von Ruboxistaurin
RU2441000C2 (ru) * 2009-11-27 2012-01-27 Общество с ограниченной ответственностью "Молекулярные Технологии" 4-(1-(4-(4-метоксифенилтио)-2,5-диоксо-2,5-дигидро-1н-пирро-3-ил)-1н-индол-3-ил)бутилкарбамимидотиоат и способ его применения
ES2385157B1 (es) * 2010-02-25 2013-07-08 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer.
BR112012024585A2 (pt) 2010-03-30 2016-05-31 Novartis Ag inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicas
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2847191B1 (de) 2012-05-09 2016-06-15 Sanofi Substituierte 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridin-derivate als kinaseinhibitoren
PL2925366T3 (pl) 2012-11-29 2018-08-31 Novartis Ag Kombinacje farmaceutyczne
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
HRP20191283T1 (hr) 2014-01-24 2019-10-18 Turning Point Therapeutics, Inc. Diaril makrocikli kao modulatori protein kinaze
WO2016003450A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Pkc-epsilon inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
EP4397665A3 (de) 2015-07-06 2024-08-21 Turning Point Therapeutics, Inc. Diarylmakrozykluspolymorph
DK3325488T3 (da) * 2015-07-21 2020-09-14 Turning Point Therapeutics Inc Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer
CN106854141A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4-氯甲苯化合物的合成方法
CN107778148A (zh) * 2016-08-30 2018-03-09 湖南华腾制药有限公司 一种溴化苄衍生物的合成方法
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
WO2018175340A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
BR112020001695A2 (pt) 2017-07-28 2020-07-21 Turning Point Therapeutics, Inc. compostos macrocíclicos e usos dos mesmos
CN111511746B (zh) 2017-12-19 2024-01-09 特普医药公司 用于治疗疾病的巨环化合物
EP4201403A1 (de) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Verbindungen tirapazamin und quazinon zur verwendung bei der behandlung von gm2-gangliosidosen
US20230203017A1 (en) * 2021-12-28 2023-06-29 Kamal D. Mehta Protein Kinase C Beta Inhibitors and Uses Thereof
JP2026505008A (ja) * 2023-01-27 2026-02-10 メリセル，インコーポレイテッド 肥満および脂肪細胞肥大化に関連する疾患の治療のための方法および組成物
CN121358745A (zh) * 2023-04-21 2026-01-16 4M治疗公司 N-去甲基鲁伯斯塔及其盐的多晶型物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808613A (en) * 1986-11-21 1989-02-28 Bristol-Myers Company Rebeccamycin derivative containing pharmaceutical composition
US4785085A (en) * 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
EP0303697B1 (de) * 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivate des physiologisch aktiven mittels k-252
FR2614022B1 (fr) * 1987-04-15 1989-12-01 Roussel Uclaf Nouveaux derives 17-aza de 20,21-dinoreburnamenine, leur procede de preparation et les nouveaux intermediaires ainsi obtenus, leur application comme medicaments et ces compositions les renfermant
US5438050A (en) * 1988-02-06 1995-08-01 Godecke Aktiengesellschaft Indolocarbazole derivatives, processes for their preparation and compositions containing them
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
SK75289A3 (en) * 1988-02-10 1998-05-06 Hoffmann La Roche Substituted pyrroles, their use for producing a drug, and the drug on their base
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
IL94274A0 (en) * 1989-05-05 1991-03-10 Goedecke Ag Maleinimide derivatives,process for the preparation thereof and pharmaceutical compositions containing the same
DE3914764A1 (de) * 1989-05-05 1990-11-08 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
DE3924538A1 (de) * 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
DE3942296A1 (de) * 1989-12-21 1991-06-27 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung
DE4005970A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005969A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
JPH04187686A (ja) * 1990-11-20 1992-07-06 Meiji Seika Kaisha Ltd インドロカルバゾール誘導体
WO1992018507A1 (en) * 1991-04-11 1992-10-29 Schering Corporation Anti-tumor and anti-psoriatic agents
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
AU5100393A (en) * 1992-09-25 1994-04-26 Schering Corporation Diindolo compounds and pharmaceutical compositions containing them
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
AU678435B2 (en) * 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
JP2004269543A (ja) 2004-09-30
CA2137203C (en) 2006-11-28
FI945706A7 (fi) 1995-06-08
NO944643D0 (no) 1994-12-02
RU2147304C1 (ru) 2000-04-10
HU219709B (hu) 2001-06-28
KR950018010A (ko) 1995-07-22
NZ270048A (en) 1996-11-26
CZ301894A3 (en) 1995-06-14
IL111850A (en) 2002-11-10
MY125587A (en) 2006-08-30
PL182124B1 (pl) 2001-11-30
DE69428025D1 (de) 2001-09-27
DK0657458T3 (da) 2001-10-29
BR9404831A (pt) 1995-08-08
CN1050844C (zh) 2000-03-29
CN1220266A (zh) 1999-06-23
CN1111247A (zh) 1995-11-08
CA2137203A1 (en) 1995-06-08
CO4340622A1 (es) 1996-07-30
YU70494A (sh) 1997-03-07
US5698578A (en) 1997-12-16
DE69428025T2 (de) 2002-05-29
CN1055089C (zh) 2000-08-02
AU687909B2 (en) 1998-03-05
NO944643L (no) 1995-06-08
AU7918894A (en) 1995-06-15
GR3037087T3 (en) 2002-01-31
IL111850A0 (en) 1995-03-15
SG63570A1 (en) 1999-03-30
UA44690C2 (uk) 2002-03-15
KR100340159B1 (ko) 2002-11-23
YU49200B (sh) 2004-09-03
HK1013827A1 (en) 1999-09-10
NO308798B1 (no) 2000-10-30
PT657458E (pt) 2002-02-28
FI20011109L (fi) 2001-05-28
FI20011109A7 (fi) 2001-05-29
RU94042922A (ru) 1996-12-27
EP0657458B1 (de) 2001-08-22
FI945706A0 (fi) 1994-12-02
CY2413B1 (en) 2004-11-12
FI20000516A7 (fi) 2000-03-07
FI108138B (fi) 2001-11-30
CZ291950B6 (cs) 2003-06-18
EP0657458A1 (de) 1995-06-14
ES2162843T3 (es) 2002-01-16
JPH07215977A (ja) 1995-08-15
JP3581731B2 (ja) 2004-10-27
TW425397B (en) 2001-03-11
PE49195A1 (es) 1996-01-06
PL306084A1 (en) 1995-06-12
HU9403468D0 (en) 1995-02-28
HUT71130A (en) 1995-11-28

Similar Documents

Publication Publication Date Title
ATE204579T1 (de) Proteinkinase c-inhibitoren
MY118068A (en) Protein kinase c inhibitor
MX9707431A (es) Inhibidores de la proteina cinasa c.
ATE215954T1 (de) Pyrazolo(4,3-d)pyrimidin-derivate und diese enthaltende pharmazeutische zubereitungen
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
CO4910133A1 (es) Antagonistas de 5-h[1f]
EA199800966A1 (ru) Галогензамещенные ингибиторы протеинкиназы с
DK0916670T3 (da) Pyrrolo[3,2-b]pyridiner og deres anvendelse som 5-HT1f-agonister
EA199800368A1 (ru) Новые промежуточные продукты и их использование для получения n,n'-мостиковых бисиндолилмалеимидов
FI970318A0 (fi) Antiproliferatiivisina aineina ja Garft-inhibiitoreina käyttökelpoisia yhdisteitä
ECSP961937A (es) Inhibidor de proteina quinasa "c"